A Note on Safety We built medicinal-use.com to help make sense of the UK’s changing laws, but we aren’t doctors. This content is for research and education—it isn’t medical advice. Before changing your healthcare routine or starting a new treatment, please speak with a GMC-registered clinician. Your safety matters more than any article we write.
[my_disclaimer]
Insomnia affects around 10% of UK adults, causing significant distress, impaired daily functioning, and increased risk of other health issues like anxiety and depression. Conventional treatments (CBTi, Z-drugs, melatonin) help many but have limitations (dependency risks, side effects, availability issues). In 2025, private specialist clinics prescribe CBPMs for insomnia where other options have failed, with growing real-world evidence from UK registries showing benefits.
1. Evidence for CBPMs in Insomnia (2025 Update)
Evidence is emerging and promising, primarily from real-world patient registries rather than large RCTs.
- UK Medical Cannabis Registry Data Studies from the UK Medical Cannabis Registry (largest ongoing UK dataset) show sustained improvements in subjective sleep quality (measured by Single-Item Sleep-Quality Scale) at 1, 3, 6, and up to 18 months. Patients also report reduced anxiety, better mood, and improved health-related quality of life. Insomnia patients report changes in sleep quality and general PROMs over six months, with treatment generally well-tolerated (low adverse events ~13%).
- CBD and THC Effects Preclinical studies suggest cannabinoids influence the endocannabinoid system, which regulates sleep-wake cycles. CBD may improve sleep quality without heavy sedation, while THC can help with sleep onset but may disrupt REM sleep or cause tolerance. Balanced products (THC/CBD) are common in private practice.
- Other Evidence Real-world data from private clinics and registries show improvements in sleep latency, duration, and efficiency for some patients. Observational studies indicate reduced reliance on traditional sleep aids.
- NHS Position NICE and NHS England do not recommend CBPMs for insomnia due to limited high-quality RCT evidence. NHS access is extremely rare.
- Limitations Most data is observational (no placebo control). Long-term safety, optimal dosing, and THC/CBD ratios need more research. Some patients report no benefit or side effects like fatigue.
2. Access for Insomnia in 2025
NHS — Virtually impossible for insomnia alone (not NICE-approved).
Private Clinics — Main route for eligible patients. Eligibility: Diagnosed insomnia disorder, 2+ conventional treatments tried (e.g., CBTi, Z-drugs) with insufficient benefit/side effects, medical records.
Process (Private)
- Self-refer to CQC-regulated clinic (e.g., Releaf, Alternaleaf, Curaleaf Clinic, Mamedica, Lyphe).
- Online eligibility check/upload records.
- Specialist consultation (£50–£200).
- Prescription if suitable (often CBD-dominant or balanced THC/CBD oils for sleep).
- Medication from licensed pharmacy (home delivery).
- Follow-ups (1–3 months) for adjustments.
Costs
- Consultation: £50–£200
- Medication: £50–£400+/month (CBD-dominant often cheaper)
- Follow-ups: £65–£150
3. CBD vs THC for Insomnia
| Aspect | CBD-Dominant Products | THC-Inclusive Products |
|---|---|---|
| Effects on Sleep | May improve sleep quality, reduce awakenings | Helps sleep onset; can reduce nightmares in PTSD-related insomnia |
| Common Forms | Oils, capsules, broad-spectrum (0% THC) | Balanced THC/CBD oils, capsules, flower (vaporised) |
| Evidence | Stronger for sleep quality (less disruption) | Mixed; may help initiation but tolerance possible |
| Risks | Lower (fatigue, dry mouth rare) | Higher (tolerance, rebound insomnia on cessation, dependence) |
| UK Private Use | Often first-line for insomnia | Used when CBD alone insufficient |
Clinics typically start low/slow, preferring CBD-dominant for sleep to minimize psychoactive effects.
4. Risks and Side Effects
- Common: Dry mouth, fatigue, dizziness, appetite changes
- THC-related: Tolerance/rebound insomnia, dependence, impaired cognition, driving risks (DVLA strict)
- General: Interactions with other meds (e.g., sedatives), psychiatric effects in vulnerable people
- Long-term: Limited data; potential for tolerance or worsening sleep in some
Specialists monitor closely.
5. Legal & Practical Notes
- CBPMs are prescription-only (Schedule 2).
- Possession without prescription illegal (Class B).
- Driving: Impairment windows apply — check DVLA.
- No NHS funding for insomnia — full private cost.
Sources
- UK Medical Cannabis Registry clinical outcomes for insomnia (PLOS Mental Health, 2025)
- Curaleaf Clinic reviews and registry data
- NICE guidelines on CBPMs
- Preclinical and observational studies on cannabinoids and sleep